Four details:
- Lenzilumab seeks to neutralize GM-CSF, a cytokine linked to hospitalization and death in COVID-19 patients.
- The announcement is based on data from a 520-participant phase 3 clinical trial. Patients in both the lenzilumab and placebo groups were given other treatments, such as steroids and remadesivir.
- The Kaplan-Meier estimate for invasive mechanical ventilation and/or death was 15.6 percent for the lenzilumab group, compared to 22.1 percent for the placebo group.
- Humanigen said it has met its primary endpoint for the drug and plans to use the data to apply for FDA emergency use authorization.
More articles on pharmacy:
Vaccinations at pharmacies preferred to ones at mass vaccination sites, Biden officials say
COVID-19 vaccinations at US pharmacies to double, get closer to home
Moderna ships 100 millionth vaccine dose to US government
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
